ACADIA Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on commercializing and developing therapies for central nervous system and rare diseases. Its current business is anchored by two U.S.-approved products: NUPLAZID (pimavanserin) and DAYBUE (trofinetide). The company runs a specialty-pharmacy-centric distribution model and supports prescribing through field-based specialists and patient access services. Manufacturing and supply are largely outsourced, with a Swiss subsidiary (Acadia Pharmaceuticals GmbH) managing key intellectual property and the global supply chain for pimavanserin API manufactured in Switzerland.
9,9 %
91,7 %
36,5 %
+11,9 %
3.83
3.43
| % | |
|---|---|
| NUPLAZID (pimavanserin) | 65% Commercial sales of NUPLAZID via specialty channels, supported by marketing and distribution partners. |
| DAYBUE (trofinetide) | 30% Commercial sales of DAYBUE for Rett syndrome supported by rare disease field teams and patient services. |
| Other revenue (e.g., PRV sale/other) | 5% Non-recurring or ancillary items such as proceeds from Rare Pediatric Disease PRV sales when applicable. |
ACADIA’s direct customers are a limited set of U.S. specialty pharmacies and specialty distributors that purchase...
Purchase NUPLAZID (and potentially DAYBUE) and dispense to patients; value reliable supply, reimbursement support, and patient services.
Buy product for resale into government facilities, long-term care pharmacies, and inpatient hospital pharmacies; value compliant distribution and continuity of supply.
Physicians and institutions (including Rett Centers of Excellence) drive prescribing decisions; influenced by clinical data, education, and patient support infrastructure.
Determine coverage, prior authorization, and patient cost-sharing that directly affects uptake and persistence for specialty therapies.
ACADIA is headquartered in the United States and currently commercializes NUPLAZID and DAYBUE primarily in the U.S...
ACADIA’s near-term strategy centers on sustaining and expanding the NUPLAZID franchise while scaling DAYBUE adoption in...
DAYBUE growth depends on specialist penetration, diagnosis, and access execution.
A large portion of revenue is tied to continued demand and channel effectiveness.
Reducing dependence on two products lowers concentration risk and supports longer-term growth.
Revenue concentration risk is high because the company’s prospects are highly dependent on maintaining and growing...
A limited number of U.S.-based customers accounted for ~79% of NUPLAZID product revenue and 44% of total product revenue (FY2025), increasing exposure to channel disruption or contract changes.
API and drug product manufacturing are outsourced; regulatory actions (e.g., recalls, warning letters, site enforcement) could restrict manufacturing/marketing or force discontinuation.
If physicians/patients do not adopt products or if coverage/out-of-pocket costs worsen, demand and revenue can decline despite commercial investment.
Compromises of IT systems or vendor systems can cause operational disruption, regulatory investigations, litigation, and reputational harm.
Tax authorities may challenge intercompany pricing and income allocation related to Acadia GmbH and licensed IP, potentially increasing taxes, interest, and penalties.
ACHC · Services-Specialty Outpatient Facilities, NEC
AKBA · Pharmaceutical Preparations
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications.
AMLX · Pharmaceutical Preparations
SNDX · Pharmaceutical Preparations
Syndax Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for hematologic malignancies and other serious diseases.
SPRB · Pharmaceutical Preparations
ABOS · Biological Products, (No Diagnostic Substances)
: 11/08/2026